How do I buy Alumis Inc. Common Stock (ALMS) stock?

Buying Alumis Inc. Common Stock (ALMS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "ALMS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ALMS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ALMS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Alumis Inc. Common Stock (ALMS) Stock

Q: What is the minimum investment for ALMS on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Alumis Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · ALMS

Trade ALMS

Key stats

Market cap: $784.38M
Price / Earnings ratio: -1.9x
EPS (TTM): -$3.85
Volume: Loading
52-week high: $31.35
52-week low: $4.37

Source: third-party data provider, as of October 16, 2026

Compare with ALMS

Technical indicators

RSI 14: 21.55
MACD 12/26/9: -1.94
EMA 9 of MACD: -2.41
MACD histogram: 0.47
SMA 50: $14.42; Price below SMA 50
EMA 50: $12.75; Price below EMA 50
SMA 200: $21.95; Price below SMA 200
EMA 200: $17.48; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 5 analyst ratings

Strong Sell0

Sell0

Hold1

Buy4

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

29M19M10M0

Debt & Balance Sheet

Total assets

Total liabilities

2025

494M326M163M0

Revenue to Profit

2025

$24.1M

Revenue

$0.0

Cost of revenue

$24.1M

Gross profit

$0.0

Operating expenses

$-243.3M

Net income

Earnings

No data available

Source: third-party data provider

About Alumis Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees237

CEOMr. Martin Babler Ph.D.

IPO DateJun 28, 2024

HeadquartersSouth San Francisco, CA

Key Executives

Name	Title	Year Born
Mr. Martin Babler Ph.D.	President, CEO & Chairman	1965
Mr. John R. Schroer C.F.A.	Chief Financial Officer	1965
Dr. David M. Goldstein Ph.D.	Chief Scientific Officer	1966
Dr. Jorn Drappa M.D., Ph.D.	Chief Medical Officer & Head of Research and Development	1965
Ms. Sanam Pangali J.D.	Chief Legal Officer & Corporate Secretary	1984
Mr. Roy C. Hardiman J.D.	Chief Business & Strategy Officer	1960
Ms. Claire Langrish Ph.D.	Senior VP & Head of Immunology and Translational Science	—
Mr. Philip Nunn Ph.D.	Senior VP of Pharmacology & Project Team Leader	—
Mr. Mark Bradley	Chief Development Officer	1966
Mr. Kolbot By Ph.D.	Senior VP & Head of Technical Operations	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024						+0.0	-1.9	+0.1	-12.5	+6.1	-18.1	-5.0
2025	-9.0	-37.5	+35.2	-42.8	-8.6	-8.8	+37.1	+12.3	-15.1	+17.0	+68.2	+32.8
2026	+173.5	+12.4	-25.9	+8.6	-14.2	+38.4	+6.0	-16.5	-22.0	-16.0

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Alumis Inc. Common Stock (ALMS) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "ALMS", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ALMS by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Alumis Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Alumis Inc. Common Stock (ALMS) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ALMS's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Alumis Inc. Common Stock (ALMS) Stock

Key stats

Compare with ALMS

Recent news

ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis eyes late-stage lupus study despite trial miss

Alumis eyes late-stage lupus study despite trial miss

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis eyes late-stage lupus study despite trial miss

Alumis eyes late-stage lupus study despite trial miss

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million

An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential

Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

About Alumis Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade